The Journal of Immunology, Vol 146, Issue 3 870-878, Copyright © 1991 by American Association of Immunologists

ARTICLES

Hyperphosphorylation of CD20 in hairy cells. Alteration by low molecular weight B cell growth factor and IFN-alpha

E Genot, MA Valentine, L Degos, F Sigaux and JP Kolb
Unite INSERM 196, Institut Curie, Paris, France.

Hairy cell leukemia (HCL) is a B cell tumor affecting the pre-plasma stage of B cell differentiation. Hairy cells produce B cell growth factor (BCGF)-related growth factor(s) and we have previously shown that low mol wt (LMW)-BCGF-induced proliferation of hairy cells is inhibited in vitro and in vivo by IFN-alpha. We therefore suggested that this effect might contribute to the exquisite sensitivity of HCL to IFN-alpha therapy. To elucidate the mechanism involved in the therapeutic effect of IFN-alpha, we have analyzed the pattern of phosphorylated proteins in hairy cells. We detected the presence of a hyperphosphorylated protein with a molecular mass of about 35 kDa. This protein was identified as the CD20 molecule (B1), which is a structurally unique phosphoprotein exclusively detected on B cells and expressed during most stages of B cell development. Incubation of hairy cells with mitogenic concentrations of LMW-BCGF induces an additional increase in CD20 protein phosphorylation. In contrast, preincubation of cells with IFN-alpha, but not IFN-gamma, decreases both basal and LMW- BCGF-induced CD20 phosphorylation. CD20 phosphorylation in hairy cells is also reduced after in vivo IFN-alpha administration. In contrast, in one case of a patient unresponsive to IFN-alpha therapy, CD20 phosphorylation is not altered by in vitro IFN-alpha treatment, whereas LMW-BCGF still elicits CD20 phosphorylation stimulation. Our results suggest that IFN-alpha may act in HCL, at least in part, by inhibiting leukemic cell proliferation via regulation of phosphorylation, since CD20 phosphorylation is thought to be associated with cellular proliferation. A model involving dysregulation of CD20 is discussed.

This article has been cited by other articles:

				B. Chaigne-Delalande, L. Deuve, E. Reuzeau, C. Basoni, D. Lafarge, C. Varon, F. Tatin, G. Anies, R. Garand, I. Kramer, et al. RhoGTPases and p53 Are Involved in the Morphological Appearance and Interferon-{alpha} Response of Hairy Cells Am. J. Pathol., February 1, 2006; 168(2): 562 - 573. [Abstract] [Full Text] [PDF]

				C. M. Jubala, J. W. Wojcieszyn, V. E. O. Valli, D. M. Getzy, S. P. Fosmire, D. Coffey, D. Bellgrau, and J. F. Modiano CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma Vet. Pathol., July 1, 2005; 42(4): 468 - 476. [Abstract] [Full Text] [PDF]

				J. Uchida, Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, et al. Mouse CD20 expression and function Int. Immunol., January 1, 2004; 16(1): 119 - 129. [Abstract] [Full Text] [PDF]

				I. Jilani, S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Blood, November 15, 2003; 102(10): 3514 - 3520. [Abstract] [Full Text] [PDF]